SAHA联合顺铂对肾上腺皮质癌SW-13细胞增殖抑制作用的研究

欧阳可育; 胡卫列; 聂奇伟

SAHA联合顺铂对肾上腺皮质癌SW-13细胞增殖抑制作用的研究

- 1. 南方医科大学研究生学院 (广州, 510515);
- 2. 广州军区广州总医院泌尿外科, 解放军泌尿外科中心, 广州军区泌尿外科研究所
基金项目:
国家自然科学基金资助项目（编号81172421）

详细信息

通讯作者: 胡卫列,E-mail:huwl-mr@vip.sina.com

中图分类号: R736.6

收稿日期: 2013-08-22

Study on the proliferation inhibition of suberoylanilide hydroxamic acid and cisplatin in adrenocortical carcinoma SW-13 cell line

- 1. Graduate School of Southern Medical University, Guangzhou, 510515, China;
- 2. Department of Urology, Guangzhou General Hospital of Guangzhou Military Command

More Information

Corresponding author: HU Weilie, E-mail: huwl-mr@vip.sina.com

Received Date: 22 August 2013

摘要

摘要: 目的：研究SAHA（辛二酰苯胺异羟肟酸）与顺铂联合应用对肾上腺皮质癌SW-13细胞生长增殖的抑制作用，初步探讨两种药物联合运用于治疗肾上腺皮质癌的可能性。方法：采用WST-8法检测肾上腺皮质癌SW-13细胞对单独使用SAHA或顺铂时的剂量反应；检测低剂量的SAHA及顺铂联用对肾上腺皮质癌SW-13细胞的毒性作用；分别在普通光学显微镜及荧光显微镜下对经各种处理的细胞进行凋亡形态学观察，采用流式细胞术对凋亡进行量化。结果：随单独用药剂量的增加，肾上腺皮质癌SW-13细胞对SAHA及顺铂呈现出较好的敏感性；低剂量的SAHA（1 μmol/L）和顺铂（16 mg/L）联合应用较之两种药物的单独使用能显著提高药物对肾上腺皮质癌SW-13细胞的生长抑制作用（P<0.01）；细胞凋亡形态学观察和流式细胞术结果也表明联合处理组的SW-13细胞凋亡特征更明显。结论：SAHA可以有效增强肾上腺皮质癌SW-13细胞对低剂量顺铂的敏感性。
- 肾上腺肿瘤 /
- 皮质癌 /
- 辛二酰苯胺异羟肟酸 /
- 顺铂 /
- 细胞增殖
Abstract: Objective: To evaluate the feasibility of SAHA combined with cisplatin in treatment of adrenocortical carcinoma (ACC) by studying the inhibition of the growth of SW-13 cell line in adrenocortical carcinoma.Method: A pilot study was firstly used to observe the response to a dosage of SAHA or cisplatin alone in adrenocortical carcinoma SW-13 cell. Subsequently, low dose of SAHA combined with cisplatin was used to detect cytotoxicity through WST-8. The morphological characteristics of apoptosis in treated cells were observed under both ordinary optical microscope and fluorescence microscope. Flow cytometry assay was used to quantify apoptosis.Result: Adrenocortical carcinoma SW-13 cells were more sensitive to either SAHA or cisplatin alone along with the increasing dosage. Low dose of SAHA combined with cisplatin showed more sensitive to SW-13 cell line in adrenocortical carcinoma compared with either subtoxic SAHA (1 μmol/L) or cisplatin (16 mg/L) alone (P<0.01). The morphological characteristics and flow cytometry also confirmed that there were much more apoptotic SW-13 cells in combinational treatment group.Conclusion: Concurrent treatment of SAHA and cisplatin enhances cytotoxicity in adrenocortical carcinoma SW-13 cell line.
- adrenocortical carcinoma /
- SAHA /
- cisplatin /
- cell proliferation /

HTML全文

参考文献(6)

[1]	Rikiishi H, Shinohara F, Sato T, et al. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid[J]. Int J Oncol, 2007, 30(5):1181-1188.
[2]	Suzuki M, Endo M, Shinohara F, et al. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells[J]. Cancer Chemother Pharmacol, 2009, 64(6):1115-1122.
[3]	Dong G, Luo J, Kumar V, et al. Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells[J]. Am J Physiol Renal Physiol, 2010, 298(2):293-300.
[4]	Bookman M A, Greer B E, Ozols R F, et al. Optimal therapy of advanced ovarian cancer:carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5[J]. Int J Gynecol Cancer, 2003, 13(6):735-740.
[5]	Zhu W G, LakShinanan R R, Bea1 M D, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors[J]. Cancer Res, 2001, 61(4):1327-1333.
[6]	Kelly WK, Marks PA. Drug insight:Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid[J]. Nat Clin Pract Oncol, 2005, 2(3):150-157.